Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).
According to the company, the session will be webcast live with a replay available afterward on Eledon’s website under Events.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
While ELDN is down 2.71%, several biotech peers are also lower today, including MCRB (-8.65%) and NKTX (-8.07%). However, the momentum scanner shows no confirmed sector-wide move, suggesting today’s action is more stock-specific than part of a broad rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Phase 1b kidney data | Positive | -4.0% | Long-term Phase 1b tegoprubart kidney transplant data with favorable safety and eGFR. |
| Jan 08 | Business update | Positive | +0.0% | 2025 progress, 2026 tegoprubart outlook, and financing expected to fund into 2Q 2027. |
| Dec 01 | Conference participation | Neutral | -6.1% | Announcement of participation in the 37th Annual Piper Sandler Healthcare Conference. |
| Nov 18 | Islet transplant data | Positive | -4.9% | Preliminary tegoprubart data in islet transplant showing insulin independence with no major toxicities. |
| Nov 14 | Earnings and financing | Neutral | -8.0% | Q3 2025 results, BESTOW Phase 2 data, and $57.5M equity financing for programs. |
Recent ELDN news, even when clinically or strategically positive, has often coincided with flat or negative price reactions, pointing to a pattern of weak follow‑through on announcements.
Over the last few months, ELDN has reported multiple clinically focused and corporate updates. On Nov 14, 2025, it paired Q3 2025 results with financing and Phase 2 BESTOW data. Subsequent news on Nov 18, 2025 and Jan 23, 2026 highlighted encouraging tegoprubart data in islet and kidney transplantation, while a Jan 8, 2026 outlook detailed funding into 2Q 2027. Despite these developments, most events were followed by flat or negative price moves, providing context for how today’s conference participation fits into a cautious trading backdrop.
Market Pulse Summary
This announcement highlights ELDN’s ongoing investor-relations efforts via participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. In recent months, the company has paired similar appearances with updates on tegoprubart and financing to support development. Investors following the story may watch for any new disclosures or guidance during the fireside chat and compare messaging against prior clinical and corporate milestones reported over the past two quarters.
AI-generated analysis. Not financial advice.
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT).
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When will Eledon (ELDN) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?
How can investors watch the Eledon (ELDN) fireside chat on February 12, 2026?
Who from Eledon (ELDN) will speak at the Guggenheim Biotech Summit 2026 fireside chat?
Will Eledon (ELDN) make presentation materials or a replay available after the Guggenheim summit?
